Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-02-16
2010-02-09
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S227200, C514S227800, C514S228500, C514S231500, C544S324000, C544S054000, C544S058100, C544S059000, C544S092000, C544S098000, C544S106000
Reexamination Certificate
active
07659280
ABSTRACT:
The present invention provides 3-hydroxyphenyl-2,4-pyrimidinediamine compounds of formula I, as well as related compositions and methods for treating a variety of autoimmune diseases.
REFERENCES:
patent: 5200400 (1993-04-01), Teramoto et al.
patent: 5958935 (1999-09-01), Davis et al.
patent: 6235746 (2001-05-01), Davis et al.
patent: 7060827 (2006-06-01), Singh et al.
patent: 7070996 (2006-07-01), Rossi et al.
patent: 7122542 (2006-10-01), Singh et al.
patent: 7173028 (2007-02-01), Dahmann et al.
patent: 7332484 (2008-02-01), Singh et al.
patent: 2004/0029902 (2004-02-01), Singh et al.
patent: 2005/0026914 (2005-02-01), Buchanan et al.
patent: 2005/0209230 (2005-09-01), Singh et al.
patent: 2005/0234049 (2005-10-01), Singh et al.
patent: 2006/0135543 (2006-06-01), Singh et al.
patent: 2006/0167254 (2006-07-01), Cooper et al.
patent: 2006/0178407 (2006-08-01), Argade et al.
patent: 2006/0211657 (2006-09-01), Singh et al.
patent: 2006/0234983 (2006-10-01), Singh et al.
patent: 2006/0293311 (2006-12-01), Li et al.
patent: 2007/0060603 (2007-03-01), Singh et al.
patent: 2007/0117775 (2007-05-01), Payan
patent: 2007/0129360 (2007-06-01), Bhamidipati et al.
patent: 2007/0129362 (2007-06-01), Bhamidipati et al.
patent: 2007/0167439 (2007-07-01), Singh et al.
patent: 2007/0203161 (2007-08-01), Argade et al.
patent: 2007/0203162 (2007-08-01), Li et al.
patent: 2007/0225495 (2007-09-01), Singh et al.
patent: 2007/0293520 (2007-12-01), Singh et al.
patent: 2007/0293524 (2007-12-01), Singh et al.
patent: 2007/0299095 (2007-12-01), Singh et al.
patent: 02463989 (2004-04-01), None
patent: 0 432 893 (1991-06-01), None
patent: WO 97/19065 (1997-05-01), None
patent: WO 01/64656 (2001-09-01), None
patent: WO 02/102313 (2002-12-01), None
patent: WO 03/032997 (2003-04-01), None
patent: WO 03/063794 (2003-08-01), None
patent: WO 2004/014382 (2004-02-01), None
patent: WO 2004/080980 (2004-09-01), None
patent: WO 2005/012294 (2005-02-01), None
patent: WO 2005/013996 (2005-02-01), None
patent: WO 2005/016893 (2005-02-01), None
patent: WO 2005/016894 (2005-02-01), None
patent: WO 2005/026130 (2005-03-01), None
patent: WO 2005/026158 (2005-03-01), None
patent: WO 2005/118544 (2005-12-01), None
patent: WO 2006/034872 (2006-04-01), None
patent: WO 2006/074057 (2006-07-01), None
patent: WO 2006/078846 (2006-07-01), None
patent: WO 2007/006926 (2007-01-01), None
patent: WO 2007/085540 (2007-08-01), None
patent: WO 2007/085833 (2007-08-01), None
patent: WO 2007/098507 (2007-08-01), None
Cha et al., Journal of Pharmacology and Experimental Therapeutics, 317(2), 571-578, 2006.
Braselmann et al., Journal of Pharmacology and Experimental Therapeutics, 319(3), 998-1008, 2006.
Wolft Manfred E. “Burger's Medicinal Chemistry, 5ed, Part 1”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutices, 3ed.”, Marcel Dekker, New York. 1996, pp. 451 and 596.
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Vippagunta et al., Advanced Drug Delivery Reviews 48: 3-26, 2001.
Bean-Knudsen et al. (1989) Porcine mast cell leukemia with systemic mastocytosis, Vet. Pathol. 26(1):90-92.
Carreras et al. (1993) Activated T cells in an animal model of allergic conjunctivitis, Br. J. Ophthalmol 77(8):509-514.
Chan et al. (2001) Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis, J. Invest. Dermatol. 117(4):977-983.
Claman et al. (2001) Immunoglobulin dysregulation in murine graft-vs-host disease: a hyper-IgE syndrome, Clin. lmmunol. Tmmunopathol. 56(1):46-53.
Demo et al. (1999) Quantitative measurement of mast cell degranulation using a novel flow cytometric annexin-V binding assay, Cytometry 36(4):340-348.
Erion et al. (2004) Design, synthesis, and characterization of a series of cytochrome P(450) 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver, J. Am. Chem. Soc. 126(16):5154-5163.
Foster (1995) The pathophysiology of ocular allergy: current thinking, Allergy 50(21Suppl):6-9; discussion 34-38.
Hakim et al. (1996) A nine-amino acid peptide from IL-1beta augments antitumor immune responses induced by protein and DNA vaccines, J. Immunol. 157(12):5503-5511.
Hough et al. (1998) A model for spontaneous B-lineage lymphomas in IgHmu-HOX11 transgenic mice, Proc. Natl. Acad. Sci. USA 95(23):13853-13858.
Kawaguchi et al. (1994) Nasal mast cells in experimentally induced allergic rhinitis in guinea-pigs, Clin. Exp. Allergy 24(3):238-244.
Kunert et al. (2001) Alteration in goblet cell numbers and mucin gene expression in a mouse model of allergic conjunctivitis, Invest. Ophthalmol. Vis. Sci. 42(11):2483-2489.
Mocsai et al. (2002) Syk is required for integrin signaling in neutrophils, Immunity 16:547-558.
Monteiro and van de Winkel (2003) IgA Fc Receptors, Annual Review of Immunology 21:177-204.
O'Keefe et al. (1987) Systemic mastocytosis in 16 dogs, J. Vet. Intern. Med. 1(2):75-80.
Sada et al. (2001) Structure and function of Syk protein-tyrosine kinase, J. Biochem. (Tokyo) 130(2):177-186.
Saiga et al. (1992) Clinical and cytologic aspects of ocular late-phase reaction in the guinea pig, Ophthalmic Res. 24(1):45-50.
Sugimoto et al. (2000) A new model of allergic rhinitis in rats by topical sensitization and evaluation of H(1)-receptor antagonists, Immunopharmacology 48(1):1-7.
Suto et al. (1999) NC/Nga mice: a mouse model for atopic dermatitis, Int. Arch. Allergy Immunol. 120(Suppl 1):70-75.
Szelenyi et al. (2000) Animal models of allergic rhinitis, Arzneimittelforschung 50(11):1037-1042.
Tumas et al. (2001) Anti-IgE efficacy in murine asthma models is dependent on the method of allergen sensitization, J. Allergy Clin. Immunol. 107(6):1025-1033.
Turner et al. (2000) Tyrosine kinase SYK: essential functions for immunoreceptor signalling, Immunology Today 21(3):148-154.
U.S. Appl. No. 11/539,074, filed Oct. 5, 2006, Singh et al.
U.S. Appl. No. 11/782,581, filed Jul. 24, 2007, Singh et al.
U.S. Appl. No. 11/875,772, filed Oct. 19, 2007, Li et al.
U.S. Appl. No. 11/943,506, filed Nov. 20, 2007, Bhamidipati et al.
U.S. Appl. No. 12/028,581, filed Feb. 8, 2008, Argade et al.
U.S. Appl. No. 12/030,031, filed Feb. 12, 2008, Li et al.
U.S. Appl. No. 12/030,069, filed Feb. 12, 2008, Argade et al.
U.S. Appl. No. 12/053,382, filed Mar. 21, 2008, Li et al.
U.S. Appl. No. 12/053,438, filed Mar. 21, 2008, Atuegbu et al.
Bamborough et al. 2007, “N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: Indazoles as phenol isosteres with improved pharmacokinetics”Bioorganic&Medicinal Chemistry Letters17(15):4363-4368.
Ghosh 1966, “2, 4-Bis(arylamino)pyrimidines as Antimicrobial Agents”Journal of Medicinal Chemistry9:423-424.
Mackie et al. 1952, “Influence of groups in the molecule 2,3-dihydro-3-keto-1,4-benzothiazine on its effect on liver fluke (Fasciola hepatica) in vitro”.British Journal of Pharmacology and Chemotherapy, 7:219-22.
Sammond et al. 2005, “Discovery of a novel and potent series of dianilinopyrimidineurea and urea isostere inhibitors of VEGFR2 tyrosine kinase”Bioorganic&Medicinal Chemistry Letters15(15):3519-3523.
Shridhar et al. 1985, “Synthesis and anthelmintic activity of some new 6- and 7-iosothiocyanato-2H-1,4-benzoxa(thia)zin-3(4H)-ones and benzoxa(thia)zin-3(4H)-thiones.”Indian Journal of Chemistry, Section B: Organic Chemistry including Medicinal Chemistry, 24B(12):1263-7.
Traxler, 1997 “Protein Tyrosine Kinase inhibitors in cancer treatment”, Exp. Opin. Ther. Patents, 7(6):571-588.
Bhamidipati Somasekhar
Clough Jeffrey Wayne
Masuda Esteban
Singh Rajinder
Zhao Haoran
Balasubramanian Venkataraman
Klarquist & Sparkman, LLP
Rigel Pharmaceuticals Inc.
LandOfFree
2,4-pyrimidinediamine compounds for treating or preventing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2,4-pyrimidinediamine compounds for treating or preventing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2,4-pyrimidinediamine compounds for treating or preventing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4193486